Donald Trump 2.0: Since winning the presidential election in the United States, Donald Trump’s policies are being discussed all over the world. In such a situation, under Trump’s China +1 policy, this could be an opportunity for Indian pharmaceutical companies to gain benefits due to the reduction of China’s integration in the manufacturing of drugs in the American pharma market and its supply chain.
Apart from this, experts say that due to increase in tariff on Chinese goods, Indian pharmaceutical companies can play a big role in meeting the required supply in the generic drug market of America.
America is an important market for Indian pharmaceutical companies
Experts further said that America has always been an important market for Indian pharmaceutical companies. In which its participation in total sales is 30 percent and market share is 40 percent. However, there may be some risk with changes in duty structure and geopolitical policies. India has firmly established itself in the global generic drug market, which is now well positioned to benefit from changes in US trade and supply policies.
Indian companies should see the opportunity
Sujay Shetty, Global Health Industries Advisory Leader, PwC India, told Times of India that Donald Trump’s government is going to come with an America First policy and an agenda of low taxes and low inflation. In which Indian companies should look at the opportunity to become a part of the supply chain. He said that the agenda for Donald Trump’s second term will become clear in the coming weeks. But there are some important aspects of his previous presidency, in which America First trade policy, reduction in foreign dependence and security (especially from China) are important.
Also read:
